Semaglutide is a medication that belongs to a class of drugs called GLP-1 receptor agonists. It was originally developed to help people manage type 2 diabetes and, later, obesity, and it has been sold under brand names like Ozempic, Wegovy, and Rybelsus. When researchers and clinicians began tracking patients using semaglutide for weight loss, they noticed something unexpected: many of those patients were also reporting sharp reductions in their desire to drink alcohol, use drugs, or engage in compulsive behaviors. This pattern prompted addiction scientists to take a much closer look at how the medication interacts with the brain.
The mechanism behind semaglutide’s effect on addiction involves the brain’s reward system. GLP-1 receptors are found in areas like the nucleus accumbens and the ventral tegmental area, which are the same regions that generate the intense feelings of pleasure and craving associated with substance use. When semaglutide activates these receptors, it appears to reduce the dopamine surge that makes alcohol or drugs feel rewarding. Patients often describe the experience as the substance simply losing its pull. For people in recovery, that quieting of the mental noise around cravings can make an enormous difference in day-to-day life.
What Does The Research Say About Semaglutide And Substance Use?
Clinical evidence for semaglutide in addiction treatment is growing quickly. A 2025 study published in JAMA Psychiatry involving 48 participants with alcohol use disorder found that semaglutide significantly reduced both alcohol cravings and actual alcohol consumption in a controlled setting. The following year, the SEMALCO trial published in The Lancet reported results from 108 participants and found a 41.1 percent reduction in heavy drinking days among those taking semaglutide, compared to 26.4 percent in the placebo group. That difference was statistically significant, and it represents a meaningful improvement over many existing treatments.
Large observational studies have added further weight to these findings. A 2026 study published in the BMJ examined health records from more than 606,000 veterans and found that people using GLP-1 medications had a 14 percent lower risk of developing any substance use disorder, experienced 39 percent fewer overdoses, and had a 50 percent lower rate of drug-related mortality. Research published in Nature Communications in 2024 found a 50 to 56 percent lower risk of alcohol use disorder incidence and recurrence among GLP-1 users. At least 33 clinical trials are currently registered to study semaglutide across alcohol, opioid, cocaine, nicotine, and cannabis use disorders.
Could Semaglutide Be Part Of An Addiction Treatment Plan?
As of 2026, semaglutide has not been approved by the FDA for addiction treatment, and any use for that purpose is considered off-label. That said, off-label prescribing is a standard and legal part of medical practice when clinicians determine it is appropriate for a specific patient. Some leading treatment programs, including Caron Treatment Centers, have already begun incorporating semaglutide into their care for select patients. If you or someone you love is seeking addiction treatment and has questions about whether semaglutide could play a role, speaking with a physician who specializes in addiction medicine is the right starting point. At Carrara Treatment, our medical team stays current with the latest evidence and works with each client individually to design a plan that makes sense for their health history, their goals, and their recovery journey.
What is semaglutide and why are doctors using it for addiction?
Semaglutide is a GLP-1 receptor agonist medication sold as Ozempic, Wegovy, and Rybelsus. Originally approved for diabetes and obesity, it was found to reduce cravings for alcohol and drugs by acting on reward centers in the brain. Doctors began using it off-label for addiction after patients and clinical studies both showed significant reductions in substance cravings and use.
Has semaglutide been proven to treat alcohol or drug addiction?
Strong early evidence exists, including a 2026 Lancet trial showing a 41 percent reduction in heavy drinking days and a BMJ study of over 600,000 veterans showing 39 percent fewer overdoses among GLP-1 users. However, semaglutide is not yet FDA-approved for addiction. Dozens of clinical trials are ongoing, and results so far are promising enough that leading treatment centers have begun using it carefully under medical supervision.
Is semaglutide available as part of addiction treatment programs?
Some specialized addiction treatment centers are already incorporating semaglutide into individualized treatment plans on an off-label basis. It is not a standalone solution but may complement therapy, counseling, and other medical supports. Anyone considering it should do so under the guidance of an addiction medicine physician who can evaluate whether it is appropriate for their specific health history and recovery needs.
